Upregulation of brain renin angiotensin system by 27-hydroxycholesterol in Alzheimer's disease.

In spite of the fact that cholesterol does not pass the blood-brain barrier, hypercholesterolemia has been linked to increase Alzheimer's disease (AD) risk. Hypertension is another risk factor and angiotensin converting enzyme (ACE) activity is known to be increased in AD. Furthermore, a lower incidence of AD has been reported in patients taking anti-hypertensive drugs. Here we show that the levels of angiotensinogen (AGT) and ACE are increased in the cerebrospinal fluid (CSF) of patients with mild cognitive impairment and AD. Moreover, we show ACE activity in the CSF to be positively correlated with both plasma and CSF levels of 27-hydroxycholesterol (27-OH), an oxysterol known to pass through the BBB and taken up from the circulation by the brain. In addition, treatment of rat primary neurons, astrocytes, and human neuroblastoma cells with 27-OH resulted in increased production of AGT. Our results demonstrate that upregulation of renin-angiotensin system (RAS) in AD brains occurs not only at the enzymatic level (ACE) but also at the substrate level (AGT). The possibility that 27-OH is part of a mechanism linking hypercholesterolemia with increased brain RAS activity and increased AD risk is discussed.

[1]  J. Palmgren,et al.  Common variants of ACE contribute to variable age-at-onset of Alzheimer’s disease , 2004, Human Genetics.

[2]  Kristine Yaffe,et al.  Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study , 2005, BMJ : British Medical Journal.

[3]  C. Sigmund,et al.  An intracellular renin-angiotensin system in neurons: fact, hypothesis, or fantasy. , 2008, Physiology.

[4]  C. Jack,et al.  Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.

[5]  G. Winocur,et al.  High-fat diets, insulin resistance and declining cognitive function , 2005, Neurobiology of Aging.

[6]  H. Arai,et al.  ACE activity in CSF of patients with mild cognitive impairment and Alzheimer disease , 2006, Neurology.

[7]  M. Iwai,et al.  Devil and angel in the renin–angiotensin system: ACE–angiotensin II–AT1 receptor axis vs. ACE2–angiotensin-(1–7)–Mas receptor axis , 2009, Hypertension Research.

[8]  B. Winblad,et al.  Low blood pressure and risk of dementia in the Kungsholmen project: a 6-year follow-up study. , 2003, Archives of neurology.

[9]  B. Winblad,et al.  Apolipoprotein E ε4 magnifies lifestyle risks for dementia: a population-based study , 2008, Journal of cellular and molecular medicine.

[10]  L. Wahlund,et al.  Diagnostic use of cerebral and extracerebral oxysterols , 2004, Clinical chemistry and laboratory medicine.

[11]  J. Egido,et al.  Inflammation and angiotensin II. , 2003, The international journal of biochemistry & cell biology.

[12]  T. Bayer,et al.  Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease Published, JLR Papers in Press, October 1, 2003. DOI 10.1194/jlr.M300320-JLR200 , 2004, Journal of Lipid Research.

[13]  J. Rusted,et al.  Angiotensin and Alzheimer´s disease: therapeutic prospects , 2004, Expert review of neurotherapeutics.

[14]  H. Okayama,et al.  Exaggeration of Focal Cerebral Ischemia in Transgenic Mice Carrying Human Renin and Human Angiotensinogen Genes , 2009, Stroke.

[15]  S. Akterin,et al.  Activity‐Regulated Cytoskeleton‐Associated Protein in Rodent Brain is Down‐Regulated by High Fat Diet in vivo and by 27‐Hydroxycholesterol in vitro , 2009, Brain pathology.

[16]  Phillips Mi.  Functions of Angiotensin in the Central Nervous System , 1987 .

[17]  J Tuomilehto,et al.  Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study , 2001, BMJ.

[18]  M. Kivipelto,et al.  High cholesterol diet induces tau hyperphosphorylation in apolipoprotein E deficient mice , 2005, FEBS letters.

[19]  H. Okayama,et al.  Continuous Activation of Renin-Angiotensin System Impairs Cognitive Function in Renin/Angiotensinogen Transgenic Mice , 2009, Hypertension.

[20]  S. Love,et al.  Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes. , 2009, American journal of translational research.

[21]  O. Halbach,et al.  The CNS renin-angiotensin system , 2006, Cell and Tissue Research.

[22]  Steve Meaney,et al.  Brain Cholesterol: Long Secret Life Behind a Barrier , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[23]  Miia Kivipelto,et al.  Are the CSF levels of 24S-hydroxycholesterol a sensitive biomarker for mild cognitive impairment? , 2006, Neuroscience Letters.

[24]  K. Chopra,et al.  Comparative studies on the memory- enhancing actions of captopril and losartan in mice using inhibitory shock avoidance paradigm , 2001, Neuropeptides.

[25]  P. Zandi,et al.  Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. , 2006, Archives of neurology.

[26]  D. Sparks.  The early and ongoing experience with the cholesterol-fed rabbit as a model of Alzheimer's disease: the old, the new and the pilot. , 2008, Journal of Alzheimer's disease : JAD.

[27]  N. Barnes,et al.  Alterations in angiotensin AT1 and AT2 receptor subtype levels in brain regions from patients with neurodegenerative disorders. , 1996, European journal of pharmacology.

[28]  M. Cassell,et al.  The angiotensinogen gene is expressed in both astrocytes and neurons in murine central nervous system , 1999, Brain Research.

[29]  I. Björkhem.  Are side-chain oxidized oxysterols regulators also in vivo? Published, JLR Papers in Press, October 23, 2008. , 2009, Journal of Lipid Research.

[30]  I. Björkhem,et al.  Oxysterols and Alzheimer's disease , 2006, Acta neurologica Scandinavica. Supplementum.

[31]  J. Nikolova,et al.  Effects of ACE-inhibitors on learning and memory processes in rats. , 2000, Folia Medica.

[32]  J. Saavedra.  Brain Angiotensin II: New Developments, Unanswered Questions and Therapeutic Opportunities , 2005, Cellular and Molecular Neurobiology.

[33]  M. Phillips,et al.  Brain renin angiotensin in disease , 2008, Journal of Molecular Medicine.

[34]  O. Ghribi.  Potential mechanisms linking cholesterol to Alzheimer's disease-like pathology in rabbit brain, hippocampal organotypic slices, and skeletal muscle. , 2008, Journal of Alzheimer's disease : JAD.

[35]  M. Mogi,et al.  Comparison of inhibitory action of candesartan and enalapril on brain ischemia through inhibition of oxidative stress , 2006, Neuropharmacology.

[36]  D. Lütjohann,et al.  Importance of a Novel Oxidative Mechanism for Elimination of Brain Cholesterol , 1997, The Journal of Biological Chemistry.

[37]  A. Cedazo-Mínguez,et al.  Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities , 2007, Journal of cellular and molecular medicine.

[38]  J. Staessen,et al.  Blood pressure, cognitive functions, and prevention of dementias in older patients with hypertension. , 2001, Archives of Internal Medicine.

[39]  Steve Meaney,et al.  Oxysterols and neurodegenerative diseases. , 2009, Molecular aspects of medicine.

[40]  C. Hock,et al.  Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer’s dementia , 2001, Neurobiology of Aging.

[41]  A. Bouthillier,et al.  Angiotensin II Controls Occludin Function and Is Required for Blood–Brain Barrier Maintenance: Relevance to Multiple Sclerosis , 2007, The Journal of Neuroscience.

[42]  R. Hellweg,et al.  Regulation of apolipoprotein E secretion in rat primary hippocampal astrocyte cultures , 2001, Neuroscience.

[43]  E. Perry,et al.  Angiotensin Converting Enzyme in Alzheimer's Disease: Increased Activity in Caudate Nucleus and Cortical Areas , 1982, Journal of neurochemistry.

[44]  D. Mostofsky,et al.  Mediation of cognitive function by high fat diet following stress and inflammation , 2005, Nutritional neuroscience.

[45]  B. Orr,et al.  Angiotensin II attenuates NMDA receptor-mediated neuronal cell death and prevents the associated reduction in Bcl-2 expression. , 2004, Brain research. Molecular brain research.

[46]  Steve Meaney,et al.  Crossing the barrier: Published, JLR Papers in Press, March 1, 2005. DOI 10.1194/jlr.M500024-JLR200 net flux of 27-hydroxycholesterol into the human brain , 2005, Journal of Lipid Research.

[47]  B. Winblad,et al.  The age-dependent relation of blood pressure to cognitive function and dementia , 2005, The Lancet Neurology.

[48]  Suzanne Craft,et al.  The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. , 2009, Archives of neurology.

[49]  A. Kumar,et al.  Angiotensinogen gene expression in neuronal and glial cells in primary cultures of rat brain , 1988, Journal of neuroscience research.

[50]  M. Phillips.  Functions of angiotensin in the central nervous system. , 1987, Annual review of physiology.

[51]  F. van Leuven,et al.  Absence of ApoE upregulates murine brain ApoD and ABCA1 levels, but does not affect brain sterol levels, while human ApoE3 and human ApoE4 upregulate brain cholesterol precursor levels. , 2009, Journal of Alzheimer's disease : JAD.